QIN YU^1,2,#, CHEN CHEN^4,5,#, HAIYAN ZHANG^6,#, JIN CHEN², JUNKANG SHEN^1,3,*, JUN YAN^5,*

BIOCELL, Vol.47, No.6, pp. 1279-1292, 2023, DOI:10.32604/biocell.2023.027553 - 19 May 2023

Abstract Background: HLA-DMA presents pathogen-derived antigens to CD4+ and CD8+ T cells, respectively, and plays a significant part in initiating the immune response. So far, the impact of HLA expression on the prognosis of BC cells is controversial, because few studies have shown that the expressions of some HLA genes are related to the improvement of the survival rate. Up till now, however, the relationship between HLA-DMA and LUAD has not yet been assessed. Methods: We analyzed the TCGA database and assessed the prognostic value of HLA-DMA in LUAD. We conducted the Kruskal–Wallis and Wilcoxon signed-rank test… More >

QINGLING TANG¹, WARDA ATIQ², SHAISTA MAHNOOR², MOSTAFA A. ABDEL-MAKSOUD³, MOHAMMED AUFY⁴, HAMID YAZ^3,*, JIANYU ZHU^5,*

Oncology Research, Vol.31, No.2, pp. 141-156, 2023, DOI:10.32604/or.2023.028548 - 10 April 2023

Abstract Though significant improvements have been made in the treatment methods for ovarian cancer (OC), the prognosis for OC patients is still poor. Exploring hub genes associated with the development of OC and utilizing them as appropriate potential biomarkers or therapeutic targets is highly valuable. In this study, the differentially expressed genes (DEGs) were identified from an independent GSE69428 Gene Expression Omnibus (GEO) dataset between OC and control samples. The DEGs were processed to construct the protein-protein interaction (PPI) network using STRING. Later, hub genes were identified through Cytohubba analysis of the Cytoscape. Expression and survival… More >

WEI BAO^1,#, QIANGUANG HAN^2,#, XIAO GUAN³, ZIJIE WANG², MIN GU^1,2,*

Oncology Research, Vol.31, No.2, pp. 181-192, 2023, DOI:10.32604/or.2023.028051 - 10 April 2023

Abstract Background: Clear-cell renal cell carcinoma (ccRCC) is the most common malignant kidney cancer. However, the tumor microenvironment and crosstalk involved in metabolic reprogramming in ccRCC are not well-understood. Methods: We used The Cancer Genome Atlas to obtain ccRCC transcriptome data and clinical information. The E-MTAB-1980 cohort was used for external validation. The GENECARDS database contains the first 100 solute carrier (SLC)-related genes. The predictive value of SLC-related genes for ccRCC prognosis and treatment was assessed using univariate Cox regression analysis. An SLC-related predictive signature was developed through Lasso regression analysis and used to determine the risk… More >

JINGYUE FU, RUI CHEN, ZHIZHENG ZHANG, JIANYI ZHAO, TIANSONG XIA^*

Oncology Research, Vol.31, No.2, pp. 157-167, 2023, DOI:10.32604/or.2023.027972 - 10 April 2023

Abstract Background: Breast cancer has become the most common malignant tumor in the world. It is vital to discover novel prognostic biomarkers despite the fact that the majority of breast cancer patients have a good prognosis because of the high heterogeneity of breast cancer, which causes the disparity in prognosis. Recently, inflammatory-related genes have been proven to play an important role in the development and progression of breast cancer, so we set out to investigate the predictive usefulness of inflammatory-related genes in breast malignancies. Methods: We assessed the connection between Inflammatory-Related Genes (IRGs) and breast cancer by… More > Graphic Abstract

YI WANG^1,#, SHANGQI CHEN^2,#, PENGCHENG YU¹, ZHEHAN BAO¹, CAN HU¹, YUHANG XIA¹, RUOLAN ZHANG¹, LI YUAN^3,4, HUA RUAN^5,*, JIANCHENG SUN^6,*

BIOCELL, Vol.47, No.5, pp. 991-1002, 2023, DOI:10.32604/biocell.2023.028587 - 10 April 2023

Abstract Aim: Scavenger receptor class B, type I (SR-BI) is an integral plasma membrane protein that has been reported to be overexpressed in various malignancies, such as renal cancer, breast cancer, and prostate cancer, and is an independent prognostic factor. However, the clinical value and expression of SR-BI in GC are unknown. Our research aimed to explore the role of SR-BI in combination with immune markers as a diagnostic and prognostic marker for gastric cancer (GC). Methods: GC tissues, paracancerous tissues, and clinicopathological data of 149 patients were collected. The expression level of SR-BI, Tumor-infiltrating lymphocytes (TILs),… More >

SHA LI^1,2,#, YAQIONG LIU^3,#, CHAOLING YAO¹, ANJI XU¹, XIAOLING ZENG⁴, YUXIN GE⁴, XIAOWU SHENG⁴, HAILIN ZHANG^1,2, XIAO ZHOU^1,2,*, YING LONG^1,2,*

BIOCELL, Vol.47, No.5, pp. 1003-1019, 2023, DOI:10.32604/biocell.2023.027209 - 10 April 2023

Abstract Background: Nuclear receptor binding SET domain protein-3 (NSD3) is a histone lysine methyltransferase and a crucial regulator of carcinogenesis in several cancers. We aimed to investigate the prognostic value and potential function of NSD3 in 33 types of human cancer. Methods: The data were obtained from The Cancer Genome Atlas. Kaplan-Meier analysis, CIBERSORT, gene set enrichment analysis, and gene set variation analysis were performed. The expression of NSD3 was measured using quantitative real-time polymerase chain reaction and western blot. Results: The expression of NSD3 was altered in pan-cancer samples. Patients with higher levels of NDS3 generally had… More >

XI YANG^1,5,#, HUIXIAN WU^2,3,#, CHAO XIONG^4,#, BO ZHAO¹, MEILIAN LIU¹, JIE QIN⁶, MEI DENG^1,2,3,*

BIOCELL, Vol.47, No.5, pp. 1021-1037, 2023, DOI:10.32604/biocell.2023.027103 - 10 April 2023

Abstract Background: Cytochrome b561 (CYB561) plays a critical role in neuroendocrine function, cardiovascular regulation, and tumor growth; however, the prognostic value of CYB561 in patients with breast cancer and the relationship between CYB561 expression and immune infiltration in breast cancer remain unclear. Methods: The mRNA expression and clinical data of patients with breast cancer were obtained from The Cancer Genome Atlas database. Functional enrichment analysis was used to explore underlying biological functions associated with CYB561. The methylation status of CYB561 was analyzed using the MethSurv database. The enrichment score of immune cell infiltration for CYB561 in breast… More >

GANG WANG^#, MINGPING QIAN^#, WEI JIAN, JUHANG CHU, YIXIANG HUANG^*

Oncology Research, Vol.31, No.1, pp. 63-70, 2023, DOI:10.32604/or.2022.028168 - 01 March 2023

Abstract Circular RNA (circRNA), as a newly discovered non-coding RNA with important regulatory potential, is closely related to the occurrence and progression of various tumors. This study aimed to investigate has_circ_0000069 expression in breast cancer and its influence on cellular activities. Using real-time quantitative polymerase chain reaction, has_circ_0000069 levels were measured in 137 pairs of tissue specimens, as well as cancer cell lines. The cellular activities of cell lines were determined by cell counting kit-8 (CCK-8) and Transwell assays. The potential targeting miRNAs were predicted and verified using an online database and dual-luciferase reporter assay. Has_circ_0000069… More >

QING GAO^1,#, YUJING SHI^2,#, YUANYUAN SUN^1,#, SHU ZHOU¹, ZEYUAN LIU³, XINCHEN SUN^1,*, XIAOKE DI^1,*

Oncology Research, Vol.31, No.1, pp. 35-61, 2023, DOI:10.32604/or.2022.028193 - 01 March 2023

Abstract Aging is highly associated with tumor formation and progression. However, little research has explored the association of aging-related lncRNAs (ARLs) with the prognosis and tumor immune microenvironment (TIME) of head and neck squamous cell carcinoma (HNSCC). RNA sequences and clinicopathological data of HNSCC patients and normal subjects were downloaded from The Cancer Genome Atlas. In the training group, we used Pearson correlation, univariate Cox regression, least absolute shrinkage/selection operator regression analyses, and multivariate Cox regression to build a prognostic model. In the test group, we evaluated the model. Multivariate Cox regression was done to screen… More >

YUNAN MAO^1,#, JINZE SHEN^1,#, LI FANG², FENG ZHU^1,*, SHIWEI DUAN^1,*

Oncology Research, Vol.31, No.1, pp. 1-12, 2023, DOI:10.32604/or.2022.027359 - 01 March 2023

Abstract miRNAs are endogenous small RNAs that are important regulators of gene expression. miR-1294 was found to be significantly down-regulated in 15 cancers and regulated by 21 upstream regulators. miR-1294 affects the proliferation, migration, invasion, and apoptosis of cancer cells. The target genes of miR-1294 are involved in the PI3K/AKT/mTOR, RAS, and JAK/STAT signaling pathways. Six target genes of miR-1294 are the targets of a variety of drugs. Low expression of miR-1294 is associated with resistance to cisplatin and TMZ and a poorer prognosis in patients with ESCC, GC, EOC, PDAC, or NSCLC. Therefore, this work More >